Organ-specific response to [Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors.

Fiche publication

Date publication

décembre 2024

Journal

Endocrine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr MALOUF Gabriel , Pr IMPERIALE Alessio , Dr POROT Clémence , Dr BALTZINGER Philippe

Tous les auteurs :
Mamulashvili Bessac D, Baltzinger P, Poterszman N, Pham Van F, Collen C, Malouf GG, Ouvrard E, Kaseb A, Porot C, Ben Abdelghani M, Addeo P, Mertz L, Goichot B, Imperiale A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39714577

Résumé

To evaluate organ-specific response to [Lu]DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in patients with small intestine neuroendocrine tumor (SiNET) through [Ga]DOTATOC PET/CT, and to analyze tumor uptake and functional volume variations at different metastatic sites in relation to disease progression during clinical follow-up after treatment.